Ken Griffin Repligen Corp Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$119.79 - $167.35 $5.61 Million - $7.83 Million	-46,800 Reduced 45.09%	57,000 $8.48 Million
Q2 2024 Aug 14, 2024	SELL	$120.0 - $182.95 $11.5 Million - $17.6 Million	-96,000 Reduced 48.05%	103,800 $13.1 Million
Q1 2024 May 15, 2024	BUY	$170.78 - $208.42 $24.5 Million - $29.8 Million	143,200 Added 253.0%	199,800 $36.7 Million
Q4 2023 Feb 14, 2024	BUY	$114.17 - $185.35 $4.3 Million - $6.99 Million	37,700 Added 199.47%	56,600 $10.2 Million
Q3 2023 Nov 14, 2023	SELL	$138.78 - $176.51 $138,780 - $176,510	-1,000 Reduced 5.03%	18,900 $3.01 Million
Q2 2023 Aug 14, 2023	SELL	$138.42 - $180.31 $2.13 Million - $2.78 Million	-15,400 Reduced 43.63%	19,900 $2.82 Million
Q1 2023 May 15, 2023	SELL	$154.26 - $198.1 $4.7 Million - $6.04 Million	-30,500 Reduced 46.35%	35,300 $5.94 Million
Q4 2022 Feb 14, 2023	BUY	$162.42 - $220.56 $2.18 Million - $2.96 Million	13,400 Added 25.57%	65,800 $11.1 Million
Q3 2022 Nov 14, 2022	BUY	$160.42 - $256.21 $1.72 Million - $2.74 Million	10,700 Added 25.66%	52,400 $9.81 Million

488

54.2M

341K

235K

Ticker RGEN
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 55,491,200
Market Cap $7.98B
Description
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.